Paratek Pharmaceuticals, Inc. Information Request Form

Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of Paratek by Gurnet Point Capital (“Gurnet”). As a result of the merger, Paratek stockholders are anticipated to receive only $2.15 share and a contingent value right of $0.85 per share. Paratek management will receive a windfall of $40.6 million under the Company’s Revenue Performance Incentive Plan. The Paratek merger investigation concerns whether the Board of Paratek has harmed stockholders by agreeing to enter into the transaction with Gurnet and whether all material facts have been properly disclosed to stockholders.